KPRX - Kiora Pharmaceuticals, Inc. Stock Price, Fair Value and News

$3.43-0.02 (-0.58%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KPRX Price Action

Last 7 days

-3.9%

Last 30 days

-6.5%

Last 90 days

-2.6%

Trailing 12 Months

535.2%

KPRX RSI Chart

KPRX Valuation

Market Cap

10.3M

Price/Earnings (Trailing)

1.85

Price/Sales (Trailing)

3.77

EV/EBITDA

-0.31

Price/Free Cashflow

2.12

KPRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KPRX Fundamentals

KPRX Revenue

Rev. Growth (Qtr)

-100%

KPRX Earnings

Earnings (TTM)

5.5M

Earnings Growth (Yr)

40.77%

Earnings Growth (Qtr)

-53.64%

KPRX Profitability

EBT Margin

-462.53%

Return on Equity

18.48%

Return on Assets

14.41%

Free Cashflow Yield

47.28%

KPRX Investor Care

Shares Dilution (1Y)

251.23%

Diluted EPS (TTM)

1.27

KPRX Alerts

GOLDMAN SACHS GROUP INC reported owning 6.1% of KPRX [2024-11-12]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	3.2M	3.0M	2.7M	2.7M
2018	1.3M	1.4M	1.7M	1.7M
2017	839.9K	753.6K	554.0K	407.5K
2016	0	453.8K	568.5K	683.2K
2015	339.1K	0	0	0
2014	210.4K	215.0K	219.7K	224.4K
2013	0	0	0	205.7K

Get all data in R, Python etc through our Historical Stock Data APIs

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

CEO	Dr. Brian M. Strem Ph.D.
WEBSITE	kiorapharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	12

Kiora Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Kiora Pharmaceuticals, Inc.? What does KPRX stand for in stocks?

KPRX is the stock ticker symbol of Kiora Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kiora Pharmaceuticals, Inc. (KPRX)?

As of Wed Dec 04 2024, market cap of Kiora Pharmaceuticals, Inc. is 10.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KPRX stock?

You can check KPRX's fair value in chart for subscribers.

Is Kiora Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether KPRX is over valued or under valued. Whether Kiora Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Kiora Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KPRX.

What is Kiora Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 04 2024, KPRX's PE ratio (Price to Earnings) is 1.85 and Price to Sales (PS) ratio is 3.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPRX PE ratio will change depending on the future growth rate expectations of investors.